Abivax (AAVXF) Non Operating Interest Expenses (2024 - 2026)

Abivax has reported Non Operating Interest Expenses for 3 years, with the latest figure at -$5.6 million in Q1 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 21.05% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$131.3 million, a 438.79% decrease from a year earlier, with the FY2025 full-year figure at -$130.1 million, down 616.4% from the prior year.
• Non Operating Interest Expenses was -$5.6 million for Q1 2026 at Abivax, up from -$10.8 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was -$388968.7 in Q4 2024, with the low at -$108.8 million in Q3 2025.
• Average Non Operating Interest Expenses over 3 years is -$17.8 million, with a median of -$7.1 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses tumbled 2672.68% in 2025, then gained 21.05% in 2026.
• Over 3 years, Non Operating Interest Expenses stood at -$388968.7 in 2024, then sank by 2672.68% to -$10.8 million in 2025, then surged by 48.23% to -$5.6 million in 2026.
• The last three Non Operating Interest Expenses figures came in at -$5.6 million (Q1 2026), -$10.8 million (Q4 2025), and -$108.8 million (Q3 2025), per Business Quant data.